B of A Securities Maintains Buy on Oscar Health, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Adam Ron maintains a Buy rating on Oscar Health (NYSE:OSCR) and raises the price target from $22 to $25.
May 20, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities analyst Adam Ron maintains a Buy rating on Oscar Health and raises the price target from $22 to $25.
The Buy rating and increased price target from a reputable analyst at B of A Securities is likely to positively influence investor sentiment and drive short-term price appreciation for Oscar Health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100